A protein that stops cells from dividing in response to damage or stress could be a new biomarker or therapeutic target for ...

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

1 provide one explanation. The KSHV cyclin directs cellular cyclin-dependent kinase 6 (CDK6) to phosphorylate cellular Bcl-2, an inhibitor of apoptosis. Phosphorylation renders Bcl-2 unstable ...

Cyclin-dependent kinases (CDKs) are protein kinases involved in critical cellular processes, such as cell cycle or transcription, whose activity requires association with specific cyclin subunits.

For decades, cancer researchers and pharmaceutical companies have eyed cyclin-dependent kinase (CDK7) with interest due to its role as a "master regulator" of cell proliferation. CDK7 does this in ...

Ryvu Therapeutics has initiated the Phase II trial, POTAMI-61, dosing the first subject with a small-molecule cyclin-dependent kinase (CDK) 8/19 inhibitor, RVU120, for treating myelofibrosis (MF).

Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be ...

That deal included a $50 million upfront payment. CDK inhibitors, which treat cancer by blocking overactive cyclin-dependent kinases, are big business in breast cancer. Earlier this month an ...

"We are excited to outline a clear path for Zentalis to bring azenosertib to patients with Cyclin E1+ PROC,” said Ingmar Bruns, M.D., Chief Medical Officer. "In a patient population with a clear unmet ...